4 results
The purpose of this study is to provide long-term safety data for Exelon® capsule and transdermal patch treatments, in particular the effect of Exelon® on worsening of the underlying motor symptoms of Parkinson*s Disease (PD), in patients with mild…
The primary objective of the study is to evaluate the safety, tolerability, PK, and PD of AL002 administered in single ascending doses in healthy participants and multiple doses in participants with mild to moderate AD.
Primary: efficacy of dabrafenib and trametinib combination therapy compared to placebo with respect to relapse-free survival in patients with completely resected, histologically confirmed, BRAF V600E/K high risk, stage III cutaneous melanoma.…
To evaluate the efficacy of AL002 in participants with Early AD in delaying disease progression compared to standard of care